VRELysin
AXP000227.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- Intralytix
- Sponsor
- Intralytix
Names
| Name | Type | Source |
|---|---|---|
| VRELysin | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Enterococcus bacteriophage (cocktail)
- Replication
- replicating
- Route
- oral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05715619 | Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects | Suspended | Phase 1/2 | 2023-10-25 | 2026-10-31 | 80 | Vancomycin-Resistant Enterococcal Colonization |
Recent changes
No changes recorded in its trials yet.
Notes
Oral phage cocktail against vancomycin-resistant Enterococcus, in healthy and VRE-colonised subjects (phase 1/2a NCT05715619, suspended).
How to cite
VRELysin (AXP000227.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000227.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.